13 recruiting, 5 completed, 4 active not recruiting, 1 not yet recruiting. 25 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Recruiting 13, Completed 5, Active not recruiting 4, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 11 | Recruiting 8, Active not recruiting 1, Completed 1, Unknown 1 |
Follow Mixed Phenotype Acute Leukemia: new trials by email Literature Review of Mixed Phenotype Acute Leukemia trials Research Report on Mixed Phenotype Acute Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Orca-T - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Recruiting | Orca Biosystems, Inc. | 80 | 2025-12-09 | 2026-07-07 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation Donor-derived Natural Killer Cell - Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia | Phase 2 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 15 | 2025-05-09 | 2025-12-01 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-10-26 |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-10-30 |
| Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Biospecimen Collection - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | PedAL BCU, LLC | 960 | 2022-04-18 | 2026-08-25 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-11-06 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Busulfan, Fludarabine, Total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 300 | 2021-09-30 | 2026-03-18 |
| Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia Humanized CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2021-06-01 | 2021-06-02 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Azacitidine, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2020-05-05 | 2026-10-05 |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation revumenib, cobicistat - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Syndax Pharmaceuticals | 447 | 2019-11-05 | 2026-10-09 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Ziftomenib, Midazolam, Itraconazole - Advanced Malignant Neoplasm, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | Kura Oncology, Inc. | 263 | 2019-09-12 | 2026-05-13 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 235 | 2018-01-18 | 2026-03-10 |
Showing 20 of 25. Sign in to see all of them.
Leukemia, Biphenotypic, Acute (25) · Leukemia, Myeloid, Acute (20) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Myelodysplastic Syndromes (9) · Leukemia (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Burkitt Lymphoma (5) · Blastic Plasmacytoid Dendritic Cell Neoplasm (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma (4) · Hematologic Neoplasms (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3)
Hemic and Lymphatic Diseases (25) · Leukemia, Lymphoid (24) · Lymphatic Diseases (24) · Lymphoproliferative Disorders (24) · Hematologic Diseases (23) · Immune System Diseases (23) · Immunoproliferative Disorders (23) · Neoplasms (23) · Neoplasms by Histologic Type (23) · Leukemia, Myeloid (19) · Leukemia (18) · Pathological Conditions, Signs and Symptoms (12) · Bone Marrow Diseases (11) · Chronic Disease (11) · Disease Attributes (11)
Cyclophosphamide (8) · Whole-Body Irradiation (8) · Cytarabine (6) · Mycophenolic Acid (5) · Specimen Handling (5) · fludarabine (5) · fludarabine phosphate (5) · venetoclax (5) · Cyclosporine (4) · Cyclosporins (4) · Azacitidine (3) · Calcium Dobesilate (3) · Decitabine (3) · Dexamethasone (3) · Filgrastim (3)
Fred Hutchinson Cancer Center (8) · M.D. Anderson Cancer Center (3) · The First Affiliated Hospital of Soochow University (2) · Center for International Blood and Marrow Transplant Research (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Kura Oncology, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Orca Biosystems, Inc. (1) · PedAL BCU, LLC (1) · St. Jude Children's Research Hospital (1) · Syndax Pharmaceuticals (1) · University of Florida (1) · University of Washington (1) · Vironexis Biotherapeutics Inc. (1)
United States (22) · Canada (4) · Australia (3) · Puerto Rico (3) · China (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · Belgium (1) · Israel (1) · Lithuania (1) · Netherlands (1) · New Zealand (1) · Russia (1)
Phuong Vo, MD (2) · Abhishek Maiti, MBBS (1) · Angela R Smith, M.D. (1) · Ann Dahlberg (1) · Betul Oran (1) · Brenda M. Sandmaier (1) · Elias Jabbour (1) · Jordan Milner, MD (1) · Kuo-Kai Chin, MD (1) · Marie Bleakley (1) · Mary-Beth M. Percival (1) · Michele S Redell (1) · Naveed Ali, MD (1) · Rachel Salit (1) · Rishi S Kotecha (1)
PMID 33741715, PMID 34267079, PMID 30335787, PMID 32077361, PMID 32896301, PMID 33027528, PMID 33049057, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 36175988, PMID 36922593, PMID 38867582, PMID 39121437, PMID 39362248, PMID 40332046, PMID 40523209, PMID 40535475, PMID 40997296, PMID 41619724, PMID 41621809, PMID 42448319, PMID 42616616
P30CA015704 (3), U10CA180886 (2), P01CA018029 (1), P01CA078902 (1)